Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

17.50USD
21 Jul 2017
Change (% chg)

$-0.10 (-0.57%)
Prev Close
$17.60
Open
$17.70
Day's High
$17.70
Day's Low
$17.31
Volume
1,830,406
Avg. Vol
3,746,402
52-wk High
$32.74
52-wk Low
$8.32

Select another date:

Mon, Jul 17 2017

Photo

Valeant to sell Obagi Medical Products business for $190 million

Valeant Pharmaceuticals International Inc , said on Monday it would sell its Obagi Medical Products business for $190 million in cash, as part of the Canadian drugmaker's efforts to cut down its debt.

Valeant to sell Obagi Medical Products business for $190 mln

July 17 Valeant Pharmaceuticals International Inc, said on Monday it would sell its Obagi Medical Products business for $190 million in cash, as part of the Canadian drugmaker's efforts to cut down its debt.

BRIEF-Valeant agrees to sell Obagi Medical Products business

* Says ‍Valeant will use proceeds from sale to permanently repay term loan debt under its senior secured credit facility​

BRIEF-Valeant announces redemption of about $500 mln senior notes

July 13 Valeant Pharmaceuticals International Inc

BRIEF-Valeant pays down $811 million of senior secured term loans

* Valeant pays down $811 million of senior secured term loans

BRIEF-Valeant says Bausch + Lomb unit introduces Aqualox lenses to Japan

July 6 Valeant Pharmaceuticals International Inc :

BRIEF-Valeant pharmaceuticals completes sale of Dendreon to Sanpower Group

* Valeant pharmaceuticals completes sale of Dendreon to Sanpower Group

Hedge fund Paulson & Co discloses 6.3 percent stake in Valeant

New York-based hedge fund Paulson & Co on Monday reported a 6.3 percent stake in embattled Canadian drugmaker Valeant Pharmaceuticals International Inc .

UPDATE 1-Hedge fund Paulson & Co discloses 6.3 pct stake in Valeant

June 26 New York-based hedge fund Paulson & Co on Monday reported a 6.3 percent stake in embattled Canadian drugmaker Valeant Pharmaceuticals International Inc .

REFILE-Hedge fund Paulson & Co declares 6.3 pct stake in Valeant

June 26 New York-based hedge fund Paulson & Co on Monday reported a 6.3 percent stake in Canada's Valeant Pharmaceuticals International Inc,.

Select another date: